Launch of New Terumo-sponsored Randomized Study Investigating Distal Radial Access: DISCO RADIAL First patient enrolled in the DISCO RADIAL study

January 21, 2020

LEUVEN, BELGIUM - January 21, 2020 - Terumo Europe NV, a leading medical device company, announces the launch of a new randomized clinical trial: the DIStal vs COnventional RADIAL access trial (DISCO RADIAL). The trial compares the novel distal radial access with conventional radial access approach, in terms of radial occlusion rates (RAO) at discharge.

Transradial approach is the preferred vascular access for coronary angiography and interventions. Recently, the distal radial artery from the anatomical snuffbox on the dorsal side of the hand ("distal TRA" or "snuffbox access") has emerged as an alternative access to the conventional forearm radial artery for coronary angiography and interventions.

DISCO RADIAL is the first large international randomized study designed to investigate the benefits of distal radial access over conventional radial access approach. The study plans to enrol 1300 patients, in 13 centers in Europe and Japan. The patients will be randomly assigned to one of the two access groups.

DISCO RADIAL aims to generate clinical evidence on the potential benefits of this novel distal access approach over the conventional radial approach, and to support the use of the distal radial approach as an alternative to the conventional radial approach.

Principal investigator Dr Saito, Interventional Cardiologist from Shonan Kamakura General Hospital, Japan, commented, "The radial approach is a small world and just one of the access methods. However, its impact on the clinical field has been proven potent and significant. Everybody was thinking we will never have anything novel in this small world. However, unexpectedly it was not true. The distal radial approach is truly novel, and nobody has evidence yet proving its advantage over the conventional radial approach. As the group of physicians working in this field, we have the responsibility to show its efficacy. That is the reason to initiate the trial."

Principal investigator Dr Aminian, Interventional Cardiologist from Centre Hospitalier Universitaire de Charleroi, Belgium, said, "This novel access has raised great enthusiasm among the radial community, despite the paucity of clinical evidence supporting its use. Beyond potential advantages related to improved operator/patient comfort, easier and shorter haemostasis, an important feature of this technique is a puncture distal to the superficial palmar arch. Distal TRA has the potential to maintain antegrade flow in the forearm radial artery during haemostatic compression, reducing thereby the risk of retrograde thrombus formation in the forearm radial artery and therefore the risk of RAO. The current available data on distal TRA is limited to relatively small prospective and retrospective case series looking primarily at the feasibility and success rates with this approach. By assessing the potential benefit and limitations of this alternative access, DISCO RADIAL will have an important clinical impact for radial operators."

Dr Christophe Giot, Chief Medical Officer, Terumo Europe, commented that this study will generate clinical evidence for this novel distal access approach, and reflects Terumo's commitment to evidence based clinical practice and to the improvement of patients' healthcare.

Enrolment is expected to be completed within one year, and results are expected to be available in 2021. Terumo, the pioneer in transradial access products, is sponsoring this new study.

About Terumo Europe NV

Terumo Europe, founded in 1971, is a core player in the EMEA healthcare market by providing best in class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets and sells a vast range of medical devices in four main business units: Hospital and Laboratory Systems, Global Pharmaceutical Solutions, Interventional Systems and Cardio Vascular Products. Terumo Europe EMEA headquarters and production facilities are located in Haasrode (Belgium), production facility in Knowsley (UK) and sales units across EMEA.

Please visit for more information.

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide, to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been bolstering healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Media Contact

Corporate Communication Dept., Terumo Corporation

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.